Poly Medicure profit slips in Q4, hit by acquisition costs
Standalone net profit fell 7% even as revenue grew. On a consolidated basis, profit dropped 29% as acquisition-related expenses weighed.
— 3 earlier stories on Poly Medicure Ltd. →What's new
- Q4 standalone net profit fell ~7% YoY to ₹8,062 lacs despite 5% revenue growth.
- Consolidated Q4 net profit dropped ~29% to ₹6,504 lacs, partly due to acquisition costs.
- Full-year standalone net profit grew just ~1.4% to ₹33,598 lacs.
Why this matters
The consolidated profit drop is twice the standalone decline, a clear sign that acquisition costs are eating into the group's earnings. Standalone margin pressure suggests the core business itself isn't fully immune either.
What we're watching
- Whether acquisition-related costs are a one-time event or a recurring drag.
- Management commentary on integration progress and cost rationalisation.
- Trend in standalone margins as revenue growth slows.
The full read
Poly Medicure's Q4 results show a business growing its top line but struggling to translate that into bottom-line gains. Standalone revenue of ₹44,301 lacs rose ~5% YoY, yet standalone net profit slipped ~7% to ₹8,062 lacs. The steeper consolidated profit drop of ~29% to ₹6,504 lacs points to acquisition-related costs weighing on the group. For the full year, standalone net profit of ₹33,598 lacs managed just ~1.4% growth. Hardly moving. The board's ₹3.5 per share dividend is a routine shareholder return. The real story is the margin compression, particularly in the consolidated numbers, and what it means for the company's acquisition strategy. There is no new guidance or commentary to explain the cost pressures.
Questions answered
- Why did consolidated profit fall so much more than standalone profit?
- The consolidated profit decline of ~29% was partly due to acquisition-related costs that do not appear in the standalone numbers. This suggests the acquired entity is currently diluting group profitability.
- How did the top line perform?
- Standalone revenue for Q4 was ₹44,301 lacs, up about 5% year-on-year. The filing does not provide consolidated revenue figures.
- What does the full-year profit picture look like?
- Full-year standalone net profit was ₹33,598 lacs, a modest ~1.4% increase year-on-year. This shows stagnation in the core business's earnings power.
- What is the significance of the dividend?
- The ₹3.5 per share dividend represents a 70% payout on face value. It is a routine shareholder return with no implied signal about future growth or cash needs.
Poly Medicure Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on POLYMED →- 25 May 2026 · 3:23 PM IST Poly Medicure profit slips in Q4, hit by acquisition costs
- 46d ago Poly Medicure's Q4 profit drops 29% as acquisition costs bite
- 46d ago Poly Medicure walks back PendraCare revenue, renal growth targets
- 46d ago Poly Medicure's Q4 profit drops 7% standalone, 29% consolidated on acquisition costs